What is Phlecs Full Body?
The medical device works with Blue LED (light- emitting diodes) Light at a very specific wavelength and can reduce the accelerated proliferation of keratinocytes1. It can further decrease the inflammatory response in the skin1, 2. One treatment equals 15 minutes per body side
Who is Phlecs Full Body for?
Phlecs Full Body targets all plaque psoriasis adult patients. In particular, physicians might find it beneficial to use Phlecs Full Body on the following patient profiles:
• Patients for whom alternative treatments are not effective enough9. 87.8% of patients and 98.0% of dermatologists have a moderate to strong need for better plaque psoriasis treatments6.
• Patients who have reached their maximum level of UV dosage. thresholds to trigger skin cancer screening start at 200 PUVA and respectively 500 UV treatments7.
• Untreated patients. Up to half of the mild psoriasis patients (49.2%) are untreated, which can be due to alternative treatments not being convenient and thus leading to a low compliance9 .
Why Phlecs Full Body?
• Blue LED light is clinically proven to decrease symptoms of plaque psoriasis3, 4, 5.
• Gentle and safe UV-free treatment3, 4.
• Easy handling for the operator with a single on/off button and an auto-timing treatment duration of 15 minutes per body side.
• Relaxing experience for the patient due to the warm Blue LED Light during the treatment.
What is the intended treatment regimen?
Typical treatment regimen irradiating each body side for 15 minutes have investigated in a multi-site clinical trial.
Phlecs Full Body is a medical device for the treatment of plaque psoriasis (psoriasis vulgaris) in adults over the age of 18. Before altering or stopping any prescribed medication or using the device, patients should consult with their physicians.
1 Liebmann J, Born M, Kolb-Bachofen MV. Blue-Light Irradiation Regulates Proliferation and Differentiation in Human Skin Cells.Journal of Investigative Dermatology. 2010; 130: 259 – 269. 422.
2 Fischer M et al. Blue light irradiation suppresses dendritic cells activation in vitro. Experimental Dermatology. 2013; 22:554 – 563.
3 Weinstabl, A., et al. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology, 2011; 223(3): 251 – 9.
4 Pfaff S et al. Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris. Dermatology, 2015; 231: 24 – 34.
5 Krings, L., Liebmann, J., Born, M., Leverkus, M., Felbert, V. von. Data on file. July 2017.
6 Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results frmo the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. American Journal of Clinical Dermatology. Feb 2016; 17(1); 87-97.
7 British Association of Dermatologists. Phototherapy Service Guidance. 2017. Retrieved 19 Jan 2018, from http:// www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=4151
8 European S3-Guidelines on the systemic treatment of psoriasis vulgaris; JEADV; October 2009, Volume 23, Supplement 2.
9 Armstrong AW, Robertson AD, Wu, J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. Oct 2013; 149(10):1180-5.